| [1］ Blank SK, McCartney CR, Marshall JC. The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome[J]. Hum Reprod Update,2006,12(4): 351-361. [2］ Teede HJ, Meyer C, Norman RJ. Insulin-sensitisers in the treatment of polycystic ovary syndrome[J]. Expert Opin Pharmacother, 2005,6(14):2419-2427. [3］ Baillargeon JP, Nestler JE. Polycystic ovary syndrome: a syndrome of ovarian hypersensity to insulin?[J]. Clin Endocrinol Metab,2006,91(1):122-124. [4］ Rosenfield RL. Ovarian and adrenal function in polycystic ovary syndrome[J]. Endocrinol Metab Clin N Am，1999，28(2): 265-293. [5］ Poretsky L, Chandrasekher YA, Bai C, et al. Insulin receptor mediates inhibitory effect of insulin, but not of insulin-like growth factor (IGF)-I, on IGF binding protein 1 (IGFBP-1) production in human granulosa cells[J]. J Clin Endocrinol Metab，1996，81(2): 493-496. [6］ James WD .Acne[J]. N Engl J Med,2005,352:1463-1472. [7］ Azziz R.The evaluation and management of hirsutism[J]. Obstet Gynecol,2003,101:995-1007. [8］ Costello MF, Shrestha B, Eden J,et al. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review[J]. Hum Reprod ,2007,22(5):1200-1209. [9］ Nader S,Riad-Gabriel MG, Saad MF.The effect of desogestrel-containing oral contraceptives on glucose tolerance and leptin concentrations in hyperandrogenic women[J]. J Clin Endocrinol Metab,1997,82(7):3074-3077. [10］ Crosby PD, Rittmaster RS.Predictors of clinical response in hirsute women treated with spironolactone[J]. Fertil Steril, 1991, 55(6), 1076-1081. [11］ Ganie MA, Khurana ML, Eunice M, et al.Comparison of Efficacy of Spironolactone with Metformin in the Management of Polycystic Ovary Syndrome: An Open-Labeled Study[J]. J Clin Endocrinol Metab,2004,89(6):2756-2762. [12］ Velazquez E,Acosta A,Mendoesa SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome[J].Obstet Gynecol,1997,90(3):392-395. [13］ Siebert TI, Viola MI, Steyn DW,et al.Is metformin indicated as primary ovulation induction agent in women with PCOS?A systematic review and meta-analysis[J].Gynecol Obstet Invest，2012，73:304-313. [14］ Eisenhardt S, Schwarzmann N, Henschel V,et al.Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial[J]. J Clin Endocrinol Metab,2006,91(3):946-952. [15］ Lord JM, Flight IH,Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis[J]. Br Med J,2003,327(5):951-957. [16］ Kashyap S, Wells GA, Rosenwaks Z. Insulin-sensitizing agentsas primary therapy for patients with polycystic ovary syndrome[J]. Hum Reprod,2004,19(11):2474-2483. [17］ Palomba S, Falbo A, Orio F Jr, et al.Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials[J]. Fertil Steril, 2009,92(5):1646-1658. [18］ Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis[J]. Fertil Steril, 2006,86(3):658-663. [19］ Lautatzis ME, Goulis DG, Vrontakis M.Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: A systematic review[J]. 2013,Epub ahead of print. [20］ Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial[J]. J Clin Endocrinol Metab,2001,86(4):1626 1632. [21］ Du Q, Yang S, Wang YJ, et al.Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials[J].Adv Ther,2012,29(9):763-774. |
